Vitiligo is an important skin disease of childhood. The authors briefly discuss the etiopathobiology, clinics and comorbidities of the disease.
Introduction
Vitiligo is an acquired, chronic, pigmentary disorder characterized by the progressive loss of cutaneous melanocytes and abnormality in their normal function, resulting in hypopigmented skin areas which progressively become amelanotic [1] .
Different studies underline how half of vitiligo patients develop the disease before the age of 20 years old and how about 25% of them develop the disease before the age of 8 [2] .
In pediatric age, vitiligo may represent a deep psychological trauma for both patients and their parents, and leads to a poor quality of life [3] . Even if the treatment of the disease is mail goal for dermatologists, a better understanding of vitiligo may be helpful for a better management of the patient.
Etiology
As well-known, vitiligo is inherited in a nonMendelian, multifactorial and polygenic pattern.
A part for gene encoding molecules relevant for the normal melanogenesis (e.g. TYR which encode for Tyrosinase), recent studies show a strong association of vitiligo with particular HLA haplotypes (HLAs-A2, -DR4, -DR7, and -DQB1*0303) and other genes (Tab. 1) which are implicated in both cellular and humoral immunity [4] [5] [6) . Because the possible associated to different autoimmune diseases, in future, the recognition of the genetic background should be helpful to recognize eventual comorbidities and personalized focused treatment. 
Environmental factors
Many data support the deep impact of environmental factors in the development of vitiligo. First at all, there is the evidence of a variable prevalence of the disease in different countries, which range from 0.1 to 2.0%.
Then there are the data about the incidence of the disease among familiarities. It has been estimated that most of the cases of vitiligo are sporadic and up to 20% of patients report an affected relative. Moreover, the incidence of concordance of vitiligo in monozygotic twins is only 23% [7] . Different environmental factors (Tab. 2) may trigger the disease: their recognition would be fundamental to limit the incidence and progression of the skin disease. 
Pathobiology
Today the exact pathobiology of vitiligo is still unclear. Even if multiple theories have been proposed (Tab. 3), recent data support that vitiligo is a T-cell mediated autoimmune disease, triggered by oxidative stress [8] . In melanocytes, the progressive accumulation of reactive oxygen species (ROS) causes DNA damage, lipid and protein peroxidation. Many are the proteins altered, showing partial or complete loss of their functionality. In particular tyrosinase is found to be inhibited by the high concentrations of hydrogen peroxide [9] . Also keratinocytes are significantly altered by oxidative stress, leading to a deficit of their trophic support to melanocytes [10] . 
Clinic of vitiligo
Classically, vitiligo is characterized by asymptomatic white macules, varying in form and size. Although it is more often localized on body folds, periorificial and sun-exposed areas, vitiligo may affect different part of the body, both cutaneous and mucosal. Occasionally, patients may show the damage of the hair follicles' melanocytes, which result in depigmentated hairs (also known as "leukotrichia"). Characteristic is the Koebner's phenomenon, consisting in the development of new lesions at sites of skin trauma. In addition to such more common clinical features, vitiligo patients may also show abnormalities of the melanocytes localized in different districts (e.g. eyes, ears, brain, heart and lungs) [13] .
Classification
Another classification of the skin disease, often preferred to the first one, is based on the clinical feature and natural history of vitiligo (Tab. 6) [14] . Recognize the type of vitiligo has important implication for the management of the patient, because for each form there is a different prognosis (Tab. 7). 
Comorbidities
The increased risk of developing autoimmune diseases of vitiligo patients is a well-known data (Tab. 8) [15] . Even if at the moment no laboratory biomarker are available to evaluate the possible association with autoimmune comorbidities, it is recommended to rule out the presence of associated diseases thought the commonest autoimmune antibodies and clinical laboratory data (Tab. 9). In conclusion, vitiligo may be considered as a spectrum of diseases with different clinical presentations, unknown etiology, fragmented genetic data and pathobiological hypothesis. We strongly affirm the importance of a better knowledge of the etio-pathobiology and clinic of the disease, for a better management of the patients.
